Tevogen Bio’s Strategic Moves Amid Nasdaq Compliance Issues
Company Announcements

Tevogen Bio’s Strategic Moves Amid Nasdaq Compliance Issues

Tevogen Bio Holdings (TVGN) just unveiled an update.

Tevogen Bio Holdings Inc. has repurchased all outstanding shares of its Series B Preferred Stock from SSVK Associates, LLC, reassuming $3.6 million in liabilities without affecting its last reported balance sheet. Meanwhile, the company faces challenges with Nasdaq’s minimum bid price requirement, having received notice that its stock price fell short of the $1 threshold over 35 consecutive days. Tevogen has 180 days to rectify the situation before potentially facing delisting, though it may seek an additional grace period and is exploring options to meet Nasdaq’s standards.

See more insights into TVGN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTevogen leverages Microsoft partnership to deliver target identification for HPV
TheFlyTevogen regains compliance with Nasdaq
TheFlyBoeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App